Pharmaceutisch Weekblad

, Volume 14, Issue 3, pp 127–131 | Cite as

Effects of valproate on xenobiotic biotransformation in rat liver

In vivo andin vitro experiments
  • V. Rogiers
  • A. Callaerts
  • A. Vercruysse
  • M. Akrawi
  • E. Shephard
  • I. Phillips
Recent Developments on Valproate and its Metabolites


Male Wistar rats werein vivo exposed for 2 weeks to 100 μg/ml sodium valproate by subcutaneous implantation of osmotic pumps and hepatocytes were isolated. As anin vitro model co-cultures of rat hepatocytes with epithelial cells were daily treated with valproate (25, 50, 100, 200μg/ml) for 2 weeks. In both models the cytochrome P-450 content and the enzymatic activities of 7-ethoxycoumarinO-deethylase, aldrin epoxidase and glutathioneS-transferase were determined in valproate-treated hepatocytes, in controls and in phenobarbital-induced cells. It appeared that in both systems the cytochrome P-450 content and the 7-ethoxycoumarinO-deethylase activity increased significantly after valproate treatment. On the other hand, the activities of aldrin epoxidase and glutathioneS-transferase decreased. A cDNA probe, encoding rat P450IIB2 was used to determine whether mRNAs encoding the P450IIB subfamily were induced by valproate. It became clear that the inducing effect of valproate was even more pronouncedin vitro thanin vivo.


Aldrin epoxidase 7-AlkoxycoumarinO-dealkylase Biotransformation Cytochrome P-450 Enzyme induction Glutathione transferases Hepatocytes Valproic acid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eadi MJ, Hooper WD, Dickinson RG. Valproate associated hepatotoxicity and its biochemical mechanisms. Med Toxicol 1988;3:85–106.Google Scholar
  2. 2.
    Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem 1988;34:890–7.PubMedGoogle Scholar
  3. 3.
    Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA. Valproic acid hepatic fatalities; a retrospective review. Neurology 1987;37:379–85.PubMedGoogle Scholar
  4. 4.
    Scheffner D, König S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29: 530–42.PubMedGoogle Scholar
  5. 5.
    De Wolff FA, Peters ACB, Kempen GMJ. Serum concentrations and enzyme induction in epileptic children with phenytoin and valproate. Neuropediatrics 1982; 13:10–3.PubMedGoogle Scholar
  6. 6.
    Jäger E, Rating D, Platzek T, Helge H. Induction of drug metabolism by antiepileptic drugs. Epilepsia 1980;21:196.Google Scholar
  7. 7.
    Oxley J, Hedges A, Makki KA, Monks A, Richens A. Lack of hepatic enzyme inducing effect of sodium valproate. Br J Clin Pharmacol 1979;8:189–90.PubMedGoogle Scholar
  8. 8.
    Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401–10.PubMedGoogle Scholar
  9. 9.
    Patsalos PN, Duncan JS, Shorvon SD. Effect of the removal of individual antiepileptic drugs on antipyrine kinetics in patients taking polytherapy. Br J Clin Pharmacol 1988;26:253–9.PubMedGoogle Scholar
  10. 10.
    Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF. Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 1980;30:588–92.PubMedGoogle Scholar
  11. 11.
    Carl GF, De Loach C, Patterson J. Chronic sodium valproate treatment in the rat: toxicity versus protection against seizures induced by Indoclon. Neurochemistry, 1986;8:41–5.CrossRefGoogle Scholar
  12. 12.
    Cotariu D, Evans S, Zaidman JL. Effect of sodium valproate on subcellular fraction enzymes in rat liver. Enzyme 1985;34:196–200.PubMedGoogle Scholar
  13. 13.
    Dickens M, Parsons DN. The effect of lamotrigine, a novel anticonvulsant upon hepatic drug metabolising enzyme systems in the rat and the marmoset [abstract]. In: Proceedings of the International Symposium on Clinical and Basic Aspects of Enzyme Induction and Inhibition; 1985 Jul 5–6; Essen, 1985:35.Google Scholar
  14. 14.
    Jordan BJ, Shillingford JS, Steed KP. Preliminary observations on the protein binding and enzyme inducing properties of sodium valproate. In: Legg NJ, ed. Clinical and pharmacological aspects of sodium valproate in the treatment of epilepsy. London: MCS Consultants, 1984:112.Google Scholar
  15. 15.
    Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:1143–52.PubMedGoogle Scholar
  16. 16.
    Sapeika N, Kaplan ER. Effect of the anti-epileptic drug sodium valproate on induction of hepatic microsomal P-450. Res Commun Chem Pathol Pharmacol 1975;10: 767–9.PubMedGoogle Scholar
  17. 17.
    Rogiers V, Vandenberghe Y, Callaerts A, Sonck W, Maes V, Vercruysse A. The inducing and inhibiting effects of sodium valproatein vivo on the biotransformation systems of xenobiotics in isolated hepatocytes. Xenobiotica 1988;18:665–73.PubMedGoogle Scholar
  18. 18.
    Rogiers V, Vandenberghe Y, Cornet M, Callaerts A, Sonck W, Guillourd A, et al. The use of cultures and cocultures of rat hepatocytes for the study of the effects of valproate on phase I and II biotransformation systems of xenobiotics. In: Woodhouse KW, Yelland C, James OFW, eds. The liver, metabolism and ageing. Amsterdam: Elsevier Biomedical Press, 1988:75–82.Google Scholar
  19. 19.
    Rogiers V, Vandenberghe Y, Callaerts A, Verleye G, Hertens K, Cornet M, et al. Phase I and phase II xenobiotics biotransformation in cultures and co-cultures of adult rat hepatocytes. Biochem Pharmacol 1990;40: 1701–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Phillips IR, Shephard EA, Ashworth A, Rabin BR. Cloning and sequence analysis of a rat liver cDNA coding for a phenobarbital-inducible microheterogeneous cytochrome P-450 variant: regulation of its messenger level by xenobiotics. Gene 1983;24:41–52.CrossRefGoogle Scholar
  21. 21.
    Cathala G, Savouret J-F, Mendez B, West BL, Karin M, Martial JA, et al. A method for isolation of intact, transcriptionally active ribonucleic acid. DNA 1983;2:329–34.PubMedGoogle Scholar
  22. 22.
    Fourney RM, Miyakoshi J, Day RS, Paterson MC. Northern blotting efficient RNA staining and transfer. BRL Focus 1988;10:5–6.Google Scholar
  23. 23.
    Dickinson RG, Harland RC, Elias AM. Disposition of valproic acid in the rat, dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp Ther 1979;211:583–95.PubMedGoogle Scholar
  24. 24.
    Heinemeyer G, Nau H, Hildebrandt AG, Roots I. Oxidation and glucuronidation of valproic acid in male rats. Influence of phenobarbital, 3-methylcholantrene, B-naphtoflavone and clofibrate. Biochem Pharmacol 1985;34:133–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Guguen-Guillouzo C, Clement B, Baffet G, Beaumont C, Morel-Chany E, Glaise D, et al. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp Cell Res 1983;143:47–54.PubMedGoogle Scholar
  26. 26.
    Bégué JM, Le Bigot JF, Guguen-Guillouzo A, Kiechel JR, Guillouzo A. Cultured human adult hepatocytes; a new model for drug metabolism studies. Biochem Pharmacol 1984;32:1643–6.CrossRefGoogle Scholar
  27. 27.
    Guillouzo A. Use of isolated and cultured hepatocytes for xenobiotic metabolism and cytotoxicity studies. In: Guillouzo A, Guguen-Guillouzo C, eds. Isolated and cultured hepatocytes. Paris: Les Éditions Inserm John Libbey Eurotext, 1986:313.Google Scholar
  28. 28.
    Edwards AM, Glistak ML, Lucas CM, Wilson PA. 7-Ethoxycoumarin deethylase activity as a convenient measure of liver drug metabolizing enzymes: regulation in cultured rat hepatocytes. Biochem Pharmacol 1984;33:1537–46.CrossRefPubMedGoogle Scholar
  29. 29.
    Wolff T, Guengerich FP. Rat liver cytochrome P-450 isoenzymes as catalysts of aldrin epoxidation in reconstituted monoxygenase systems and microsomes. Biochem Pharmacol 1987;36:2581–8.CrossRefPubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • V. Rogiers
    • 1
  • A. Callaerts
    • 1
  • A. Vercruysse
    • 1
  • M. Akrawi
    • 2
  • E. Shephard
    • 2
  • I. Phillips
    • 3
  1. 1.Department of ToxicologyFree University BrusselsBrusselsBelgium
  2. 2.Department of Biochemistry and Molecular BiologyUniversity College LondonLondonUK
  3. 3.Department of Biochemistry, Queen Mary and Westfield CollegeUniversity of LondonLondonUK

Personalised recommendations